Drug Profile

ATB 340

Alternative Names: ATB-340

Latest Information Update: 28 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Antibe Therapeutics
Class Acetates; Analgesics; Anti-inflammatories; Anticoagulants; Antithrombotics; Benzoates; Cardiovascular therapies; Sulfides; Vasodilators
Mechanism of Action Cyclo-oxygenase 1 inhibitors; Immunomodulators; Platelet aggregation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

No development reported Cardiovascular disorders

Most Recent Events

28 Mar 2022 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Canada (PO)
04 Aug 2020 Antibe Therapeutics plans to commence IND-enabling studies in 2021
12 Mar 2020 Chemical structure information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com